Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Docetaxel + Plinabulin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 12 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Plinabulin | NPI-2358 | Antimicrotubule Agent 12 | Plinabulin (NPI-2358) is a diketopiperazine derivative that disrupts microtubule organization, leading to cell cycle arrest in tumor cells and collapse of tumor vasculature (PMID: 16317287, PMID: 31811421). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | Docetaxel + Plinabulin | Phase I | Actionable | In a Phase I clinical trial, Plinabulin and Taxotere (docetaxel) combination treatment resulted in partial response in 25% (2/8) and minor improvement in 50% (4/8) of patients with non-small cell lung cancer (PMID: 21327495). | 21327495 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02504489 | Phase III | Docetaxel Docetaxel + Plinabulin | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) | Active, not recruiting | USA | 2 |